Duavee (Conjugated Estrogens/Bazedoxifene): History & Development

What Is Duavee and Why Was It Developed?

Duavee is an oral fixed-dose combination of conjugated estrogens (CE) 0.45 mg and bazedoxifene (BZA) 20 mg. It was designed to fill a specific clinical gap: giving postmenopausal women with an intact uterus the vasomotor and bone benefits of estrogen without requiring a progestogen to protect the endometrium.

That gap mattered because progestogens carry their own side-effect burden. In the Women's Health Initiative, the CE plus medroxyprogesterone acetate arm showed a statistically significant increase in invasive breast cancer risk compared with placebo, a finding that drove millions of women off hormone therapy in the early 2000s. Researchers needed a different strategy for endometrial protection.

The Progestogen Problem

Women who have a uterus cannot take estrogen alone. Unopposed estrogen stimulates the endometrium and raises the risk of endometrial hyperplasia and carcinoma. The conventional answer has been to add a progestogen, either a synthetic progestin or micronized progesterone. That solution works, but progestogens come with breast tenderness, mood changes, and the breast-cancer signal described above.

The scientific question behind Duavee's development was direct: could a SERM selectively block estrogen's action in the breast and uterus while allowing it to work in the brain (vasomotor), bone, and vaginal tissue? Bazedoxifene was the molecule that answered yes.

From Raloxifene to Bazedoxifene

SERMs had been used in women's health for decades. Tamoxifen (approved 1977 for breast cancer) was the first clinically relevant SERM. Raloxifene (Evista, approved 1997) showed that a SERM could prevent osteoporosis without stimulating the endometrium. But neither raloxifene nor tamoxifen adequately controlled hot flashes; raloxifene actually worsens them in some women.

Bazedoxifene was synthesized by Wyeth (later acquired by Pfizer) as a third-generation SERM with a receptor-binding and tissue-selectivity profile specifically engineered to antagonize estrogen action in the uterus and breast while acting as a partial agonist in bone. In European markets, bazedoxifene was approved as a standalone osteoporosis treatment under the brand name Conbriza before the combination product reached regulators.

The Tissue Selective Estrogen Complex (TSEC) Concept

The TSEC framework is the intellectual architecture behind Duavee. The concept, developed by Wyeth researchers and refined through academic partnerships, proposes that pairing an estrogen with a SERM produces tissue-specific effects that neither agent produces alone.

In practical terms, the TSEC model works like this:

• Brain and hypothalamus. Estrogen acts on thermoregulatory neurons in the hypothalamus to reduce vasomotor instability. Bazedoxifene does not meaningfully block this action at the doses used.
• Endometrium. Bazedoxifene competes with estrogen at uterine estrogen receptors and functions as an antagonist there. In the SMART-1 trial, endometrial hyperplasia rates at 24 months were 0% in the CE 0.45 mg/BZA 20 mg group vs. 0% with placebo, confirming effective endometrial protection without a progestogen.
• Bone. Both estrogen and bazedoxifene have agonist effects in bone, producing additive preservation of bone mineral density (BMD).
• Breast. Bazedoxifene acts as an antagonist in mammary tissue, theoretically offsetting estrogen-driven proliferative stimulation.

The elegance of the model is that one pill replaces a two-drug regimen (CE plus progestogen) while removing the tissue most associated with progestogen-related side effects from the picture.

How Bazedoxifene Differs From Earlier SERMs

Raloxifene is ER-alpha and ER-beta selective but still worsens hot flashes in perimenopausal women transitioning to menopause. Bazedoxifene binds to both ER-alpha and ER-beta with a slightly different conformational change in the receptor, producing a coactivator/corepressor recruitment pattern that differs meaningfully from raloxifene in uterine tissue. In preclinical and early-phase studies, BZA showed less uterine stimulation than raloxifene at pharmacologically equivalent doses, making it the preferred SERM partner for combination with CE.

The SMART Trial Program: Five Studies That Built the Evidence Base

The Selective estrogens, Menopause, And Response to Therapy (SMART) program was a coordinated series of five phase 3 randomized controlled trials, each addressing a different outcome domain. They collectively enrolled several thousand postmenopausal women aged 40-75 with an intact uterus.

SMART-1: Endometrial Safety and Bone (24 Months)

SMART-1 was the anchor trial. Its primary endpoint was endometrial hyperplasia at 24 months. Secondary endpoints included BMD at the lumbar spine and total hip. The published results showed that CE 0.45 mg/BZA 20 mg produced zero cases of endometrial hyperplasia over two years, meeting the FDA's pre-specified non-inferiority threshold of keeping the upper bound of the 95% confidence interval below 2%. Lumbar spine BMD increased by approximately 1.5% relative to placebo.

This trial was the regulatory centerpiece. The FDA requires demonstration of endometrial safety for any estrogen-containing product intended for women with a uterus, and SMART-1 satisfied that requirement cleanly.

SMART-2: Vasomotor Symptom Efficacy (12 Weeks)

SMART-2 enrolled women reporting seven or more moderate-to-severe hot flashes per day at baseline. The primary endpoints were mean daily frequency and severity of hot flashes at weeks 4 and 12. CE 0.45 mg/BZA 20 mg reduced mean daily hot flash frequency by approximately 74% from baseline at week 12, compared with roughly 51% reduction with placebo. The absolute reduction in daily hot flashes was about 5-6 events per day versus placebo at 12 weeks.

SMART-3: Vulvovaginal Symptoms

SMART-3 examined vaginal dryness, dyspareunia, and the vaginal maturation index. CE/BZA showed statistically significant improvement in the most bothersome vaginal symptom compared with placebo, though the effect size was more modest than for vasomotor symptoms. This result matters because vulvovaginal atrophy, now called genitourinary syndrome of menopause (GSM), is the second most common driver of menopause-related quality-of-life impairment.

SMART-4: Breast Safety and Tolerability

SMART-4 assessed mammographic breast density as a surrogate for breast tissue stimulation. Breast density did not increase significantly with CE 0.45 mg/BZA 20 mg versus placebo, unlike the density increases reported with CE plus progestogen combinations. Breast pain and tenderness rates were also lower than those typically reported with CE/MPA regimens, a clinically meaningful tolerability advantage for women who stopped prior HRT due to breast symptoms.

SMART-5: QoL, Sleep, and Mood

SMART-5 used the Menopause-Specific Quality of Life questionnaire and Pittsburgh Sleep Quality Index. CE/BZA improved sleep disturbance scores and vasomotor domain scores versus placebo. The sleep benefit was largely mediated through hot flash suppression rather than a direct sedative or anxiolytic effect of either component.

Regulatory Timeline and FDA Approval

Wyeth submitted the original New Drug Application before its 2009 acquisition by Pfizer. Pfizer completed the review process and received FDA approval on October 3, 2013. The approved indications were:

1. Treatment of moderate-to-severe vasomotor symptoms associated with menopause in women with a uterus.
2. Prevention (not treatment) of postmenopausal osteoporosis in the same population.

The approval was specifically limited to women with an intact uterus. Women who have had a hysterectomy do not need the BZA component for endometrial protection and are better served by estrogen-only therapy, which carries a more favorable breast-safety profile than CE/MPA combinations.

The European Medicines Agency approved the product under the brand name Duavive in 2014, acknowledging the same clinical data package.

Pharmacokinetics: How Sex-Specific Physiology Shapes the Drug's Behavior

Pharmacokinetic data in women are directly relevant here because the entire SMART program enrolled only women, which is an advantage over many older drug-development programs.

Conjugated estrogens are a mixture of estrone sulfate, equilin sulfate, and at least ten other estrogenic compounds derived from pregnant mare urine. After oral ingestion, intestinal and hepatic conjugation/deconjugation produces a complex array of circulating estrogens. Peak plasma estrone concentrations after CE 0.45 mg occur within 5-7 hours. Bazedoxifene reaches peak plasma concentration at approximately 2 hours, with a half-life of 28-30 hours, allowing once-daily dosing.

Body weight influences bazedoxifene exposure. Women with lower body weight achieve modestly higher BZA plasma concentrations, but no dose adjustment is required within the studied range. The effect of BMI on clinical outcomes was not pre-specified as a subgroup analysis in SMART-1, which is a gap in the available data.

Hepatic first-pass metabolism of CE generates estrogen metabolites through cytochrome P450 and sulfotransferase pathways. Strong CYP3A4 inducers (rifampin, carbamazepine) may reduce estrogen exposure; this interaction is the same as with all oral CE formulations.

Pregnancy, Lactation, and Contraception: Required Reading

Duavee is contraindicated in pregnancy. This is not a precautionary statement. The FDA pregnancy category for conjugated estrogens is Category X, meaning that known risks outweigh any potential benefit. Fetal harm is documented with exogenous sex hormones. Bazedoxifene has demonstrated teratogenic effects in animal models at doses producing exposures comparable to the human therapeutic dose.

If you could become pregnant, do not use Duavee. The drug is indicated only for postmenopausal women. Postmenopause is defined as 12 consecutive months of amenorrhea without another cause. Women in perimenopause who are still ovulating intermittently are not appropriate candidates. Any perimenopausal woman who begins CE/BZA while still capable of ovulation requires reliable contraception, because neither CE nor BZA provides contraceptive protection.

Lactation

Estrogens are present in breast milk and may reduce milk production. Bazedoxifene transfer into human breast milk has not been studied. Given that the drug is indicated only for postmenopausal women, the lactation scenario is clinically remote but not impossible in edge cases (for example, a woman who adopted and is providing donor milk). If breastfeeding is occurring for any reason, CE/BZA should not be used.

Women Who Have Not Yet Reached Menopause

The SMART trials enrolled women aged 40-75 who were postmenopausal, defined as FSH above 40 mIU/mL or 12 months of amenorrhea. Women still in perimenopause were excluded. The drug has not been studied in perimenopausal women, and using it in that population would be off-label with no supporting efficacy or safety data.

Who This Drug Is and Is Not Right For

Women Most Likely to Benefit

• Postmenopausal, uterus intact, moderate-to-severe hot flashes, not tolerating or not wanting a progestogen.
• Women who stopped prior CE/MPA therapy due to breast tenderness or who have dense breasts on mammography and want to minimize additional density increases.
• Women with osteopenia or at elevated fracture risk who also have vasomotor symptoms, since CE/BZA addresses both in one daily tablet.
• Women with PCOS who have entered menopause may carry residual cardiometabolic risk that requires careful lipid monitoring on any estrogen therapy, though CE/BZA has no specific approval or label language for this population.

Women Who Should Not Use It

• Women who have had a hysterectomy (estrogen alone is preferred).
• Women with a history of estrogen-dependent cancers (breast, endometrial, ovarian).
• Women with active or prior venous thromboembolism, stroke, or myocardial infarction.
• Women with undiagnosed vaginal bleeding.
• Women who are pregnant or may become pregnant.
• Women with known protein C, protein S, or antithrombin deficiency, given the thrombotic risk of oral estrogens.
• Women with liver dysfunction, since both components are hepatically metabolized.

How Duavee Fits Into Current Menopause Guidelines

The Menopause Society (formerly NAMS) 2023 position statement on hormone therapy states that hormone therapy remains the most effective treatment for vasomotor symptoms and supports the use of CE/BZA as an option for appropriate postmenopausal women with a uterus. The Society notes that the TSEC approach offers an alternative for women who cannot or prefer not to use a progestogen.

ACOG Practice Bulletin on Menopause also recognizes CE/BZA as an FDA-approved option within the broader hormone therapy field, noting that individual counseling about risks and benefits is required for every patient.

One evidence gap worth naming directly: the SMART trials were 24 months in duration for the primary endometrial safety endpoint. Long-term endometrial safety data beyond 24 months are more limited than the decades of data available for CE/MPA combinations. This should factor into shared decision-making for women who plan to use therapy for more than two years.

Sex-Specific Side Effects and Monitoring

Women starting Duavee should expect the following:

• Muscle spasms were the most commonly reported adverse event in SMART trials, occurring in approximately 9-10% of CE/BZA users versus 6% with placebo.
• Nausea affected about 9% of users in the first 12 weeks, typically resolving without discontinuation.
• Hot flash paradox: Unlike raloxifene, BZA does not worsen vasomotor symptoms, but some women report a transient increase in hot flashes in the first 2-4 weeks as estrogen levels stabilize.
• Thromboembolism risk is inherent to oral estrogen. The absolute risk in healthy postmenopausal women aged 50-59 is low, but women with a personal or strong family history of VTE should discuss transdermal estrogen alternatives. CE/BZA is not available in a transdermal formulation.
• Mammography: Because CE/BZA does not significantly increase breast density in SMART-4, it may be a particularly useful option for women whose prior CE/MPA therapy was making mammography harder to read.

Baseline and annual monitoring should include blood pressure, breast exam and mammography, and any unscheduled uterine bleeding (which requires endometrial evaluation even though CE/BZA protects the endometrium, because breakthrough bleeding always warrants investigation).

The Evidence Gap in Women: An Honest Account

The SMART program deserves credit for enrolling only women, studying female-specific endpoints (endometrial safety, vasomotor symptoms, bone density in a postmenopausal female skeleton), and pre-specifying sex-relevant outcomes. That stands in sharp contrast to much of the cardiovascular and osteoporosis literature, where female subgroups were added as afterthoughts.

What the SMART trials did not address: women with surgical menopause (bilateral oophorectomy), women with premature ovarian insufficiency, women of color (the race/ethnicity composition of SMART trial populations was majority White, limiting generalizability), and long-term outcomes beyond two years for endometrial histology or beyond the observational period for breast cancer incidence. The breast cancer signal, or absence of it, cannot be established from a 12-to-24-month trial program. As The Menopause Society position statement acknowledges, "the long-term breast safety of CE/BZA awaits additional data".

Women with PCOS who reach menopause are an unstudied subgroup. PCOS is associated with higher endometrial cancer risk due to anovulation-driven unopposed estrogen exposure during the reproductive years. Whether CE/BZA provides adequate endometrial protection in this group, given the pre-existing elevated baseline risk, is not established by any published trial.

Practical Dosing and Administration

The approved dose is one tablet (CE 0.45 mg/BZA 20 mg) once daily. The tablet should be swallowed whole, not crushed or chewed, because the formulation timing affects the relative absorption of both components. It can be taken with or without food.

No dose titration is available. Unlike CE/MPA combinations where the progestogen component can be cycled or dosed at different strengths, CE/BZA comes in a single fixed-dose formulation. If a woman needs more vasomotor control, the clinical options are switching to a higher-dose estrogen regimen with an added progestogen, or augmenting with non-hormonal therapies such as fezolinetant (Veozah), the NK3 receptor antagonist approved in 2023.

Women should take calcium (1,000-1,200 mg daily from diet and supplements combined) and vitamin D (1,500-2,000 IU daily) alongside CE/BZA if using it for osteoporosis prevention, since the SMART-1 BMD data were collected in women receiving calcium and vitamin D supplementation as background therapy.

Lipid panels are worth reviewing at baseline. Oral estrogens raise triglycerides through first-pass hepatic effects. Women with pre-existing hypertriglyceridemia (fasting triglycerides above 400 mg/dL) should use transdermal estrogen formulations rather than oral CE.